Meiji Yasuda Asset Management’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,005
| Closed | -$340K | – | 667 |
|
|
2025
Q1 | $340K | Hold |
3,005
| – | – | 0.01% | 519 |
|
|
2024
Q4 | $317K | Sell |
3,005
-320
| -10% | -$34.3K | 0.01% | 530 |
|
|
2024
Q3 | $359K | Sell |
3,325
-461
| -12% | -$50.3K | 0.01% | 511 |
|
|
2024
Q2 | $411K | Buy |
3,786
+351
| +10% | +$41.4K | 0.02% | 461 |
|
|
2024
Q1 | $453K | Buy |
3,435
+650
| +23% | +$81.2K | 0.02% | 451 |
|
|
2023
Q4 | $339K | Hold |
2,785
| – | – | 0.02% | 457 |
|
|
2023
Q3 | $313K | Sell |
2,785
-50
| -2% | -$6.35K | 0.01% | 517 |
|
|
2023
Q2 | $413K | Buy |
2,835
+600
| +27% | +$81.5K | 0.02% | 448 |
|
|
2023
Q1 | $289K | Sell |
2,235
-100
| -4% | -$12.6K | 0.02% | 506 |
|
|
2022
Q4 | $298 | Sell |
2,335
-270
| -10% | -$31.3K | 0.01% | 515 |
|
|
2022
Q3 | $272K | Sell |
2,605
-702
| -21% | -$77K | 0.02% | 523 |
|
|
2022
Q2 | $347K | Buy |
3,307
+910
| +38% | +$108K | 0.02% | 505 |
|
|
2022
Q1 | $307K | Sell |
2,397
-216
| -8% | -$26K | 0.02% | 532 |
|
|
2021
Q4 | $322K | Buy |
2,613
+216
| +9% | +$28.3K | 0.02% | 463 |
|
|
2021
Q3 | $341K | Buy |
2,397
+229
| +11% | +$33.7K | 0.02% | 427 |
|
|
2021
Q2 | $339K | Sell |
2,168
-931
| -30% | -$151K | 0.02% | 431 |
|
|
2021
Q1 | $482K | Buy |
3,099
+886
| +40% | +$137K | 0.04% | 352 |
|
|
2020
Q4 | $331K | Buy |
2,213
+61
| +3% | +$8.62K | 0.03% | 327 |
|
|
2020
Q3 | $284K | Sell |
2,152
-1,699
| -44% | -$222K | 0.03% | 314 |
|
|
2020
Q2 | $446K | Buy |
+3,851
| New | +$444K | 0.04% | 306 |
|
|
2020
Q1 | – | Sell |
-4,568
| Closed | -$664K | – | 472 |
|
|
2019
Q4 | $664K | Buy |
4,568
+93
| +2% | +$12.8K | 0.06% | 297 |
|
|
2019
Q3 | $596K | Buy |
+4,475
| New | +$578K | 0.05% | 333 |
|
|
2019
Q2 | – | Sell |
-4,063
| Closed | -$504K | – | 515 |
|
|
2019
Q1 | $504K | Sell |
4,063
-4,064
| -50% | -$462K | 0.04% | 359 |
|
|
2018
Q4 | $928K | Buy |
8,127
+4,064
| +100% | +$457K | 0.09% | 246 |
|
|
2018
Q3 | $519K | Hold |
4,063
| – | – | 0.04% | 357 |
|
|
2018
Q2 | $440K | Sell |
4,063
-557
| -12% | -$60.6K | 0.04% | 388 |
|
|
2018
Q1 | $489K | Buy |
4,620
+258
| +6% | +$30K | 0.05% | 374 |
|
|
2017
Q4 | $511K | Sell |
4,362
-1,195
| -22% | -$135K | 0.05% | 373 |
|
|
2017
Q3 | $632K | Hold |
5,557
| – | – | 0.06% | 316 |
|
|
2017
Q2 | $693K | Hold |
5,557
| – | – | 0.07% | 286 |
|
|
2017
Q1 | $659K | Buy |
5,557
+83
| +2% | +$9.41K | 0.07% | 290 |
|
|
2016
Q4 | $549K | Sell |
5,474
-2,318
| -30% | -$248K | 0.06% | 315 |
|
|
2016
Q3 | $984K | Buy |
7,792
+2,596
| +50% | +$321K | 0.12% | 212 |
|
|
2016
Q2 | $607K | Buy |
+5,196
| New | +$588K | 0.09% | 246 |
|
|
2014
Q3 | – | Sell |
-4,105
| Closed | -$414K | – | 379 |
|
|
2014
Q2 | $414K | Buy |
4,105
+1,195
| +41% | +$117K | 0.09% | 227 |
|
|
2014
Q1 | $267K | Buy |
2,910
+41
| +1% | +$3.78K | 0.06% | 303 |
|
|
2013
Q4 | $260K | Sell |
2,869
-1,462
| -34% | -$127K | 0.05% | 315 |
|
|
2013
Q3 | $345K | Sell |
4,331
-124
| -3% | -$9.76K | 0.08% | 233 |
|
|
2013
Q2 | $324K | Buy |
+4,455
| New | +$333K | 0.08% | 241 |
|
Other funds holding ZBH
Meiji Yasuda Asset Management's ZBH Position: Q2 2025 in Review
Meiji Yasuda Asset Management sold out of Zimmer Biomet (ZBH) in Q2 2025, closing a stake of 3,005 shares — an estimated $340K sold.
Meiji Yasuda Asset Management first reported a position in ZBH in Q2 2013 and held it in 39 quarters. The position peaked at $984K in Q3 2016. 934 funds tracked by Wall St. Rank hold ZBH as of Q2 2025.
- Meiji Yasuda Asset Management reported no remaining Zimmer Biomet position as of Q2 2025 after selling out during the quarter.
- Meiji Yasuda Asset Management sold 3,005 Zimmer Biomet shares in Q2 2025, an estimated $340K.
- Meiji Yasuda Asset Management first reported a position in Zimmer Biomet in Q2 2013 and held it in 39 quarters.
- Meiji Yasuda Asset Management's Zimmer Biomet position peaked at $984K in Q3 2016.
- 934 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2025.
Based on Meiji Yasuda Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.